RT Journal
A1 Blaha MJ, Nasir K, Blumenthal RS
T1 STatin therapy for healthy men identified as “increased risk”
JF JAMA
JO JAMA
YR 2012
FD April 11
VO 307
IS 14
SP 1489
OP 1490
DO 10.1001/jama.2012.425
UL http://dx.doi.org/10.1001/jama.2012.425
AB 
Atherosclerotic coronary heart disease (CHD) is the most common cause of morbidity and mortality in the world. The “lipid hypothesis” of CHD is clearly established: (1) circulating cholesterol plays a central role in atherogenesis and is an integral component of the requisite lesion, the coronary plaque; (2) cholesterol levels beginning in childhood predict lifetime risk of atherosclerotic CHD events in a dose-response relationship; and (3) statins lower cholesterol levels and reduce CHD and cerebrovascular events directly proportional to the degree of low-density lipoprotein cholesterol (LDL-C) lowering. As a result, guidelines from around the world support a combined lifestyle and pharmacologic approach to cholesterol lowering directed at patients with elevated CHD risk.